SOLITARIO RESOURCES CORP. financials

XPL CIK 0000917225

Source: EDGAR filings · Built 2026-06-19T03:25:18Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Working Capital 7.79M 5.62M 9.31M 4.99M 6.88M 7.88M
Net Debt -75.00K -31.00K -111.00K -281.00K -427.00K -598.00K
Return on Equity (ROE) -15.54% -23.84% -14.47% -18.15% -10.21% -4.00%
Return on Assets (ROA) -15.31% -23.30% -14.03% -17.83% -10.02% -3.95%
Current Ratio 37.26× 16.28× 15.73× 19.98× 25.94× 46.26×
Debt-to-Equity 0.00× 0.00× 0.00× 0.00× 0.00× 0.00×
Cash Conversion Ratio 0.93× 0.95× 0.87× 0.74× 0.91× 1.08×
Accruals Ratio -0.01× -0.01× -0.02× -0.05× -0.01× 0.00×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenues 0
Operating Expenses 4.43M 6.05M 4.12M 3.67M 2.19M 1.49M
Income Tax Expense (Benefit) 0 0 0 0 0 0
Net Income (Loss) Attributable to Parent -3.83M -5.37M -3.75M -3.93M -2.37M -939.00K
Earnings Per Share, Basic $-0.07 $-0.05
Weighted Average Number of Shares Outstanding, Basic 81.00M 68.74M 64.26M 58.71M
Earnings Per Share, Diluted $-0.04 $-0.07
Weighted Average Number of Shares Outstanding, Diluted 86.77M 81.00M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 82.00K 81.00K 200.00K 316.00K 462.00K 605.00K
Assets, Current 8.01M 5.99M 9.94M 5.25M 7.16M 8.05M
Assets 25.03M 23.04M 26.76M 22.03M 23.62M 23.80M
Liabilities, Current 215.00K 368.00K 632.00K 263.00K 276.00K 174.00K
Stockholders' Equity Attributable to Parent 24.67M 22.52M 25.95M 21.65M 23.18M 23.50M
Common Stock, Shares, Outstanding 90.90M 81.64M 79.59M 64.80M 62.04M 58.11M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -3.57M -5.10M -3.26M -2.90M -2.16M -1.01M
Net Cash Provided by (Used in) Investing Activities -1.78M 3.94M -4.41M 701.00K 90.00K 976.00K
Payments for Repurchase of Common Stock 0 5.00K
Net Cash Provided by (Used in) Financing Activities 5.35M 1.27M 7.56M 2.05M 1.92M 65.00K

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (XPL CIK 0000917225), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

TIL

Instil Bio, Inc.

COCP

COCRYSTAL PHARMA, INC.

LXEH

Lixiang Education Holding Co., Ltd.